Indian stocks: Visit www.stage2stocks.com →

MetaVia Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, MetaVia is in Stage 4, the downtrend phase, now in week 3 (since Oct 8, 2026). It closed at $1.39, 88.3% below its 52-week high and below its 200-day average, which is falling.

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. More about the company

$1.39
+3.73% today
$9.2M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MTVA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 54w
S4 24w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 7w → S4 11w → S1 7w → S2 9w → S3 3w → S4 6w → S1 1w → S2 6w → S3 3w → S4 54w → S1 9w → S2 1w → S1 1w → S4 24w → S1 11w → S4 6w → S1 3w → S4 2w current
Total tracked: 166 weeks across 19 stage runs.

MTVA among Biotechnology501st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…501MTVAStage 4 · wk 38−14.7%
vs 52W High
-88.3%
$0.97 lo$11.88 hi
88.3% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 3
1w13w26w
Week 3, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-25.8%
200 DMA: $1.87 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.42x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-14.7%
3M
-6.1%
6M
-8.6%
YTD
-85.5%
1Y
-87.4%
Scan Membership
Breakout Watch
Latest: 2024-07-03
4 appearances in last 60 days. First seen: 2020-03-25.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 3 · Vol 0.42x
2026-10-21S4
Wk 2 · Vol 0.53x
2026-10-20S4
Wk 2 · Vol 0.26x
2026-10-19S4
Wk 2 · Vol 0.67x
2026-10-16S4
Wk 2 · Vol 0.94x
2026-10-15S4
Wk 2 · Vol 0.62x
2026-10-14S4
Wk 1 · Vol 0.50x
2026-10-13S4
Wk 1 · Vol 0.81x
2026-10-12S4
Wk 1 · Vol 1.71x
2026-10-09S4
Wk 1 · Vol 0.62x
2026-10-08S41→4
Wk 1 · Vol 1.42x
2026-10-07S1
Wk 3 · Vol 0.39x
Moving averages & range
50 DMA
$1.56
200 DMA
$1.87
52W High
$11.88
52W Low
$0.97
5D Low
$1.23
Resistance levels (recent highs)
20d High
$1.67
60d High
$1.84
120d High
$3.85
250d High
$11.88
Next resistance
+20.1%
to 20d High
ROE
-175.7%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.3

MetaVia: quick answers

What stage is MetaVia in?

As of Oct 22, 2026, MetaVia (MTVA) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 8, 2026 and is in week 3. What the four stages mean

Is MetaVia in an uptrend?

No. MetaVia is in a Stage 4 downtrend. It trades 25.8% below its 200-day average, which is falling.

How far is MetaVia from its 52-week high?

MetaVia closed at $1.39 on Oct 22, 2026, 88.3% below its 52-week high of $11.88. Its 52-week low is $0.97.

How has MetaVia performed over the past year?

As of Oct 22, 2026, MetaVia is down 87.4% over the past year and down 85.5% so far in 2026.

Which sector and industry is MetaVia in?

MetaVia is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.